Alliance Global Partners slashed its price target for ReShape Lifesciences (NASDAQ:RSLS) to $5.50 from $10.25 but maintained its “buy” rating, citing the company’s fourth quarter results. The stock closed at $1.35 on...
Following the fourth quarter report for T2 BioSystems (NASDAQ:TTOO), Alliance Global Partners upgraded T2 to “buy” from “neutral” and raised its price target to 70 cents from 55 cents, while Canaccord Genuity reduced...
Alliance Global Partners launched coverage of NeuroOne Medical Technologies (NASDAQ:NMTC) with a “buy” rating and price target of $5.75. The stock closed at $2.09 on Dec. 2. NeuroOne’s flexible, thin-film...
Alliance Global Partners reduced its price target for T2 Biosystems (NASDAQ:TTOO) to 88 cents from $1.25 and maintained a “neutral” rating after the company reported mixed third quarter results. The stock closed at 79...
Alliance Global Partners initiated coverage of Agrify (NASDAQ:AGFY) with a “buy” rating and $32 price target. The stock closed at $16 on Oct. 29. “We see Agrify as an ancillary play on cannabis with the company’s...
Alliance Global Partners launched coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $14.50. The stock closed at $8.61 on Sept. 21. IceCure has developed and markets the IceCure family of...
Alliance Global Partners initiated coverage of Greenlane Holdings (NASDAQ:GNLN) with a “buy” rating and $6 price target. The stock closed at $2.73 on Sept. 3. Analyst Aaron Grey writes that Greenlane is now positioned...
Alliance Global Partners downgraded IMAC Holdings (NASDAQ:IMAC) to “neutral” and reduced its price target to $1.75 from $2.35 after the Center for Medicare and Medicaid Services (CMS) requested repayment of $2.9-million...
Alliance Global Partners raised its price target for ReShape Lifesciences (NASDAQ:RSLS) to $18.50 from $12, citing an improved outlook and lower-than-anticipated share count following it’s merger with Obalon...
Alliance Global Partners initiated coverage of Myomo (NYSEA:MYO) with a “buy” rating and price target of $36.50. The stock closed at $10.19 on June 9. “Myomo, in our view, represents one of the most compelling stories...